UPB

Healthcare Biotechnology

Upstream Bio, Inc.

$4.85

-0.19 -3.77% today

Price History

Not enough data

Key Stats

Market Cap

265.64M

Avg Volume

598,095

EPS

-$2.88

52W High

$33.68

52W Low

$4.67

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-1.73

P/B Ratio

0.98

P/S Ratio

84.12

EV/EBITDA

-0.03

EV/Revenue

1.67

Margins

Gross Margin 100.0%

Operating Margin (5481.0%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

(17.5%)

Return on Equity

(46.1%)

Return on Assets

(30.3%)

Liquidity & Leverage

Current Ratio

27.99

Quick Ratio

26.38

Debt / Equity

0.00

Total Cash

261.31M

Total Debt

954,000

About

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

upstreambio.com